Increased expression of TIGIT and KLRG1 correlates with impaired CD56bright NK cell immunity in HPV16-related cervical intraepithelial neoplasia

Nie, You; Liu, Dandan; Yang, Wen; Li, Yazhuo; Zhang, Lihua; Cheng, Xia; Chen, Ruyu; Yuan, Bingbing; Zhang, Guangzheng; Wang, Hongwei

doi:10.1186/s12985-022-01776-4

Virology Journal

Table 1 Comparison between peripheral blood NK cell subsets in patients from the HPV16(+) CIN groups and the HPV(−) CIN 0 group

From: Increased expression of TIGIT and KLRG1 correlates with impaired CD56^bright NK cell immunity in HPV16-related cervical intraepithelial neoplasia

	CIN 0 HPV(−) (N = 20)		CIN 0 HPV16(+) (N = 11)		CIN I HPV16(+) (N = 10)		CIN II–III HPV16(+) (N = 16)		P value
	Median	IQR	Median	IQR	Median	IQR	Median	IQR	P value
Subset distribution
CD3⁻CD56⁺NK cells (%)	16.69	11.85–20.47	14.66	6.84–19.81	10.04	7.38–19.37	14.33	8.04–22.02	0.555
CD3⁻CD56⁺NK cells (count)	256.6	177.0–380.4	194.6	136.7–305.8	307.4	155.5–344.1	232.2	179.3–373.3	0.407
CD56^bright NK cells (%)	3.090	1.258–5.195	3.420	1.918–5.423	3.030	1.830–6.990	5.730	2.518–6.965	0.303
CD56^bright NK cells (count)	8.301	3.409–12.23	5.864	4.499–6.948	7.630	5.318–10.27	12.84	6.793–23.21	0.036
CD56^dim NK cells (%)	94.95	90.31–98.02	96.38	92.70–97.94	94.60	90.78–97.79	91.33	83.90–95.45	0.099
CD56^dim NK cells (count)	248.0	166.6–365.8	183.9	129.1–302.4	296.1	149.5–333.0	214.1	146.6–354.2	0.623
CD56^dim NK cells
TIGIT⁺ (%)	83.64	79.99–88.62	80.78	70.81–88.13	77.24	70.16–82.53	80.07	75.37–88.53	0.241
TIGIT⁺ (MFI)	2388	1873–3252	2122	1306–3254	1685	1399–2301	2080	1746–3246	0.234
CD226⁺ (%)	85.50	82.95–91.89	90.20	84.59–93.78	84.65	71.54–91.45	90.19	77.74–93.78	0.628
CD226⁺ (MFI)	1447	1364–1591	1596	1171–1739	1381	825.5–1475	1617	1210–1760	0.349
NKG2A⁺ (%)	29.46	15.88–47.20	38.91	33.96–48.97	34.64	27.29–43.55	29.83	23.68–42.14	0.684
NKG2A⁺ (MFI)	174.0	161.1–459.2	234.9	206.9–518.9	204.9	179.8–281.7	197.0	166.2–1074	0.406
CD300a⁺ (%)	98.74	94.87–99.29	98.32	97.36–98.98	98.33	97.04–98.75	97.87	96.67–98.86	0.804
CD300a⁺ (MFI)	2927	2087–3686	2733	1428–3403	3476	2788–4333	2688	1955–3923	0.366
LAIR-1⁺ (%)	98.85	96.27–99.52	99.41	98.44–99.79	98.26	97.34–98.87	98.39	96.31–99.28	0.137
LAIR-1⁺ (MFI)	2086	1321–2665	2798	2283–3064	1615	1442–2464	2012	1436–2392	0.256
Siglec7⁺ (%)	83.47	72.28–93.31	79.49	74.96–89.36	76.54	59.39–87.95	79.61	65.22–92.51	0.624
Siglec7⁺ (MFI)	11,164	7120–16,912	8153	4350–13,496	6774	2256–10,904	10,199	4249–19,750	0.280
KLRG-1⁺ (%)	24.40	20.63–38.53	25.73	16.89–41.76	45.69	31.26–53.97	40.38	33.43–52.90	0.006
KLRG-1⁺ (MFI)	214.0	143.9–487.8	310.6	222.5–603.3	328.1	161.8–738.5	498.5	262.3–1020	0.122
CD56^bright NK cells
TIGIT⁺ (%)	23.02	15.12–33.16	28.72	24.55–34.03	26.34	17.79–32.73	35.24	29.63–38.51	0.019
TIGIT⁺ (MFI)	150.9	125.9–199.0	164.0	132.6–194.3	156.0	119.2–228.6	199.8	173.3–221.3	0.114
CD226⁺ (%)	96.29	94.83–98.12	97.10	93.95–97.67	97.48	76.04–98.87	96.10	93.19–97.63	0.742
CD226⁺ (MFI)	1918	1729–2218	2155	1370–2243	1717	768.1–2618	2085	1756–2324	0.916
NKG2A⁺ (%)	87.67	82.71–91.40	93.06	84.70–95.57	92.51	89.78–95.90	92.81	86.77–96.00	0.057
NKG2A⁺ (MFI)	5289	4741–7657	6854	5260–9279	6817	5103–9407	6764	4965–7938	0.291
CD300a⁺ (%)	99.57	98.49–100.0	99.56	98.62–99.94	99.21	98.69–99.69	100.0	99.03–100.0	0.362
CD300a⁺ (MFI)	7325	5285–8500	5945	4488–9307	9753	6058–12,490	8092	5945–10,576	0.199
LAIR-1⁺ (%)	99.45	97.89–99.74	99.51	99.03–99.87	99.21	97.66–99.76	99.61	98.97–100.0	0.458
LAIR-1⁺ (MFI)	2811	2434–3273	3236	2791–3737	2931	2415–3406	2692	2434–3078	0.450
Siglec7⁺ (%)	92.01	90.60–94.46	92.80	89.47–95.50	90.74	87.22–92.72	93.65	90.39–96.00	0.205
Siglec7⁺ (MFI)	5073	4134–6173	5683	4023–6452	5018	3910–5997	5782	3767–6822	0.842
KLRG-1⁺ (%)	2.470	0.745–6.345	9.710	6.703–40.37	20.64	17.87–28.00	4.240	1.560–8.998	< 0.0001
KLRG-1⁺ (MFI)	95.20	71.96–143.6	155.3	104.7–415.3	161.9	124.4–222.1	121.6	101.7–162.1	0.021

The distribution of circulating NK cell subsets and their immunophenotype was compared among the patients of HPV16(−) CIN 0 (N = 20), HPV16(+) CIN 0 (N = 11), HPV16(+) CIN I (N = 10) and HPV16(+) CIN II–III (N = 16). Kruskal–Wallis test was used to determine statistical significance. P values ≤ 0.05 were considered statistically significant and are indicated in bold

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com